Gee Hunterr you've really impressed me lately. Great post!
I do find it ironic that some are commenting that DCB produced a poor 4C, and communication hasn't been as transparent since DT left, given he's still there!... and all that data probably dropped while he was still in his board position. I trust they know what they're doing.
Also commenting that DCB might only get us to $10,$20,$30 and not $100+, while implying DCB and PL would have, is also ironic given the last 2 years the SP has only dropped and there has been no insto/pharma investment or partnership even though there has been outstanding preclinical data. DCB was hand picked by DT and PL to start the commercialisation strategy, and based on the well written 4C it seems to be in full swing. If an offer comes, and it is low then we can argue the value at that point. At this point in time, and the previous seven years, there hasnt been an offer, so I'm happy to see DCB actively doing something.
RAC Price at posting:
$1.86 Sentiment: Buy Disclosure: Held
(20min delay)